---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product comparison"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product comparison. Topics: Tetrabenazine: indication, boxed warning monitoring, and individualized oral dosing; Deutetrabenazine: indication, boxed warning monitoring, and oral dosing; Valbenazine: indication, boxed warning monitoring, and oral dosing; Approved VMAT2 inhibitors: indirect tolerability comparison of deutetrabenazine and tetrabenazine; 24 further topics. 28 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/product-comparison"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Tetrabenazine: indication, boxed warning monitoring, and individualized oral dosing

> “XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.”
> “Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy.”
> “The chronic daily dose of XENAZINE used to treat chorea associated with Huntington’s disease (HD) is determined individually for each patient.”
> “Patients who require doses of XENAZINE greater than 50 mg per day should be first tested and genotyped to determine if they are poor metabolizers (PMs) or extensive metabolizers (EMs) by their ability to express the drug metabolizing enzyme, CYP2D6.”
> “Re-emergence of chorea may occur within 12 to 18 hours after the last dose of XENAZINE”

Source: [Xenazine prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

### Deutetrabenazine: indication, boxed warning monitoring, and oral dosing

> “AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of:”
> “Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior.”
> “Titrate at weekly intervals by 6 mg per day based on reduction of chorea or tardive dyskinesia, and tolerability, up to a maximum recommended daily dosage of 48 mg”
> “Administer AUSTEDO XR with or without food in once-daily doses”
> “Maximum recommended dosage of AUSTEDO XR or AUSTEDO in poor CYP2D6 metabolizers is 36 mg per day”

Source: [Austedo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208082s018,216354s008lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

### Valbenazine: indication, boxed warning monitoring, and oral dosing

> “INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with:”
> “Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior.”
> “Chorea associated with Huntington’s disease: The initial dosage is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily.”
> “Administer INGREZZA and INGREZZA SPRINKLE orally with or without food”

Source: [Ingrezza prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209241Orig1s034lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Approved VMAT2 inhibitors: indirect tolerability comparison of deutetrabenazine and tetrabenazine

> “Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (p < 0.05 for each).”

Source: [Claassen et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5331691/)

<a id="topic-2.1.2.14-5"></a>

### Approved VMAT2 inhibitors: GRADE-based indirect comparison

> “There is low-quality evidence that tetrabenazine and deutetrabenazine do not differ in efficacy or safety.”

Source: [Rodrigues et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573977/)

<a id="topic-2.1.2.14-6"></a>

### Symptomatic antichoreic agents: open-label randomized comparison of tetrabenazine, tiapride, and olanzapine

> “We conducted a pragmatic, randomized, open-label trial across 11 centers of the French-Speaking Huntington's Network, enrolling 179 patients with Huntington's disease.”
> “Tetrabenazine was most frequently associated with mood disorders and sedation, while olanzapine caused occasional weight gain and mild increases in LDL and total cholesterol.”

Source: [Youssov et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41014964/)

<a id="topic-2.1.2.14-7"></a>

### Route of administration compared with antisense oligonucleotides and gene therapy

> “Unlike earlier approaches such as antisense oligonucleotides ( ASOs) given by spinal tap, or virus-based gene therapies delivered by brain surgery, SKY-0515 is a small-molecule compound which can be taken by mouth and can spread throughout the body. This is very similar to votoplam, another splice modulator in development for HD by Novartis and PTC Therapeutics.”

Source: [Harding (2026)](https://en.hdbuzz.net/phase-1-results-announced-for-skyhawks-drug-sky-0515/)

<a id="topic-2.1.2.14-8"></a>

### HTT lowering targets in other trials: independent commentary

> “Astute readers may notice that 70% lowering is a fair bit higher than the current target in other HTT lowering trials of around 50%. Currently, most companies have targeted the 30-50% range for HTT lowering drugs.”

Source: [Hernandez (2024)](https://en.hdbuzz.net/373/)

<a id="topic-2.1.2.14-9"></a>

### Registered trials of investigational disease-modifying therapies: mechanism, comparator, and design

| Trial | Intervention | Mechanism of action | Population | Comparison | Study design | Estimated enrolment |
| --- | --- | --- | --- | --- | --- | --- |
| INVEST-HD (NCT07326709) | “Votoplam” | “Small molecule splicing modulator” | “Early HD (CAG ≥40, UHDRS TFC=13, TMS 7-25, IS ≥90” | “Placebo” | “Randomized, double-blind, placebo-controlled, parallel-group (phase III)” | “770” |
| FALCON-HD (NCT07378644) | “SKY-0515” | “mRNA splicing modulator designed to lower mHTT and PMS1” | “Early HD; UHDRS TFC ≥10, TMS ≥6, IS ≥70” | “Placebo” | “Randomized, double-blind, placebo-controlled, dose-ranging, parallel-group (phase II/III)” | “400” |
| NCT06826612 | “Intraparenchymal infusion of SPK-10001 into caudate and putamen bilaterally” | “AAV-mediated gene therapy delivering therapeutic construct to striatum to modify disease progression” | “HD-ISS stage 1 or 2 HD; UHDRS TFC ≥11” | “Placebo/sham surgery” | “Randomized, sequential dose-escalation, quadruple-masked, parallel assignment” | “53” |
| NCT06585449 | “ALN-HTT02” | “RNA interference selectively targeting exon 1 of HTT mRNA” | “HD-ISS stage 2 or early stage 3 HD” | “Placebo” | “Randomized, double-blind, parallel assignment, single dose” | “54” |
| POINT-HD (NCT07246941) | “RG6496” | “Intrathecally administered HTT-lowering therapy; SNP-targeted approach” | “HD gene-expansion carrierss with target SNP, CAG >39, UHDRS TFC ≥10, TMS ≥6, IS ≥70” | “Placebo” | “Randomized, placebo-controlled, single-ascending-dose study with open-label extension (phase I)” | “40” |
| VO659-CT01 (NCT05822908) | “Intrathecal administration of VO659” | “ASO targeting mutant HTT and ataxin RNA to reduce toxic protein levels” | “SCA1, SCA3, HD” | “None” | “Open-label, non-randomized” | “68” |
| NCT07344519 | “ER2001” | “Small interfering RNA” | “Adults with early manifest HD who completed study ER2001-001” | “None” | “Open-label, dose-escalation, single-group (phase I)” | “8” |
| GENERATION HD2 (NCT05686551) | “Tominersen” | “Non-allele-selective ASO” | “Prodromal and early HD” | “Placebo” | “Randomized, double-blind, dose-finding trial” | “360” |
| SELECT-HD (NCT05032196) | “WVE-003” | “Allele-selective ASO” | “Early HD” | “Placebo” | “Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial” | “36” |
| PRECISE-HD (NCT07609108) | “Pridopidine” | “Sigma-1 receptor activation” | “Manifest HD (not receiving antidopaminergic medications for ≥6 months before screening)” | “Placebo” | “Randomized, double-blind, placebo-controlled, parallel-group trial with 52-week treatment period followed by a 2-year open-label extension (phase III)” | “400” |

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

> “New trials added since the last Clinical Trials Update are indicated by *. Pharmacological trials terminated are indicated by †.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-10"></a>

### Delivery routes under investigation: subcutaneous SRP-1005 as an alternative to intrathecal or neurosurgical administration

> “SRP-1005 is designed to reduce HTT expression following subcutaneous administration through a transferrin receptor 1 -mediated delivery platform intended to facilitate central nervous system (CNS) penetration.”
> “The programme is noteworthy for its systemic subcutaneous delivery approach, which, if successful, could provide an alternative to intrathecal or neurosurgical administration strategies currently being investigated for HTT-lowering therapies.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-11"></a>

### Votoplam: oral splicing modifier, 24-month extension versus natural history

> “In the interim analysis following 24 months of votoplam treatment, there was evidence of dose-dependent benefit in slowing progression on the Composite Unified Huntington's Disease Rating Scale (cUHDRS) relative to a propensity weighted natural history cohort in Stage 2 participants, with 52% and 28% slowing for 10 mg and 5 mg participants, respectively.”
> “Votoplam (formerly PTC518) is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels.”

Source: [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24)

<a id="topic-2.1.2.14-12"></a>

### Votoplam: route and 12-week PIVOT-HD primary endpoint

> “PTC518 (also known as votoplam), an orally administered huntingtin mRNA splice modulator.”
> “The study met its primary endpoint, showing dose-dependent reductions in blood HTT protein levels at week 12, along with a favourable safety and tolerability profile across all dose levels and disease stages.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-13"></a>

### Votoplam: phase 3 INVEST-HD design

> “INVEST-HD is a randomised, placebo-controlled, double-blind, phase III interventional study designed to evaluate whether votoplam slows disease progression in participants with early symptomatic HD compared with placebo.”
> “Votoplam, also referred to as HTT227 (and formerly known as PTC518), is an orally administered small-molecule HTT-lowering therapy now being developed by Novartis for HD.”
> “Participants are randomised in a 3:2 ratio to oral votoplam or placebo, with a variable double-blind treatment duration of up to 36 months, followed by a safety follow-up visit for participants not entering a separate open-label extension.”
> “The estimated enrolment is 770 participants.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-14"></a>

### SKY-0515 in relation to huntingtin-only lowering: independent trials review

> “SKY-0515 is designed to reduce both HTT and PMS1 proteins, the latter implicated in somatic CAG repeat expansion, a mechanistic process increasingly recognised as a key driver of neuronal loss in HD.”
> “This important phase II/III clinical trial of SKY-0515 will assess whether HTT and PMS1 lowering can offer greater therapeutic benefit than HTT reduction alone in early-stage HD.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-15"></a>

### SKY-0515: twelve-month data compared with natural history and phase II/III FALCON-HD

> “As previously featured in the October 2025 update, 13 Skyhawk Therapeutics has reported new interim data from the ongoing phase I/II study of SKY-0515.”
> “Treated participants demonstrated positive mean changes from baseline in cUHDRS scores over 12 months, compared with an expected decline derived from propensity-weighted analyses of Enroll-HD and TRACK-HD natural-history datasets.”
> “Skyhawk also announced completion of enrolment in the Australia and New Zealand component of the phase II/III FALCON-HD programme (004-ANZ), with 144 participants enrolled ahead of schedule, and expansion of the global FALCON-HD study (NCT07378644) 41 to eight countries.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-16"></a>

### External natural-history comparisons across HTT-lowering trials

> “Astute HDBuzz readers will have noticed that this is a similar type of comparison that was made for the AMT-130 clinical trial data which was contentious among some HD researchers.”

Source: [Harding (2026)](https://en.hdbuzz.net/phase-1-results-announced-for-skyhawks-drug-sky-0515/)

<a id="topic-2.1.2.14-17"></a>

### Tominersen: phase 3 GENERATION HD1 dosing discontinued

> “The iDMC made its recommendation based on the investigational therapy’s potential benefit/risk profile for study participants.”
> “Study participants were randomised to either 120 mg every-2-months or 120 mg every-4-months intrathecal injections of tominersen, or placebo. The study has recruited 791 participants from 18 countries around the world.”

Source: [Roche (2021)](https://www.roche.com/media/releases/med-cor-2021-03-22b)

<a id="topic-2.1.2.14-18"></a>

### Tominersen: GENERATION HD1 design and primary end points

> “in which 791 participants with manifest Huntington’s disease were randomly assigned in a 1:1:1 ratio to receive intrathecal tominersen, at a dose of 120 mg every 8 weeks or every 16 weeks, or placebo”
> “The primary end point was the change from baseline in the score on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) or Total Functional Capacity (TFC) scale at week 101.”
> “Biomarker end points included levels of mutant HTT in CSF, levels of neurofilament light protein (NfL) in CSF, and ventricular volume.”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="topic-2.1.2.14-19"></a>

### Tominersen: GENERATION HD1 ad hoc week 69 results with the every-16-week regimen

> “In the every-16-week tominersen group, the mean changes from baseline in the scores on the cUHDRS and the TFC scale did not differ significantly from those in the placebo group (−0.16 points, adjusted P=0.84; and −0.04, adjusted P=1.00, respectively)”
> “Nonetheless, these results must be interpreted with caution, given the ad hoc nature of the analysis.”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="topic-2.1.2.14-20"></a>

### Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses

> “The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume”
> “The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy”
> “A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component”
> “More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group”
> “The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy”
> “this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="topic-2.1.2.14-21"></a>

### Tominersen: GENERATION HD2 discontinued, July 2026

> “On 9th July 2026, Roche announced the discontinuation of the GENERATION HD2 (NCT05686551) 22 study of tominersen in people with prodromal and early Huntington's disease.”
> “GENERATION HD2 confirms that sustained lowering of mHTT in humans, even if it lowers wild-type as well, and does not target HTT exon 1, is associated with robust NfL lowering - often taken as indicating reduced rates of neuroaxonal damage - but that clinical benefits, if they are to emerge, may take longer than 16 months.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-22"></a>

### Tominersen: phase 2 GENERATION HD2 unblinding anticipated in late 2026, November 2025, superseded in July 2026

> “GENERATION HD2 is a phase II, randomised, double-blind, placebo-controlled, dose-finding clinical trial comparing 60 mg tominersen, 100 mg tominersen and placebo.”
> “The clinical trial remains ongoing, and definitive conclusions regarding clinical benefit will only be possible once the data are unblinded and fully analysed. This is anticipated to be late 2026.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-23"></a>

### RG6496: allele-selective intrathecal antisense oligonucleotide, POINT-HD terminated

> “RG6496 is a selective ASO designed to lower mHTT protein while largely preserving expression of the wild-type protein.”
> “It is administered intrathecally and achieves allele selectivity by targeting a single nucleotide polymorphism (SNP) present on the expanded huntingtin gene (HTT) allele.”
> “POINT-HD was terminated following new findings from a longer-term non-clinical study indicating that RG6496 could not be administered chronically with repeated dosing.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-24"></a>

### Pridopidine: phase 3 PROOF-HD and EMA opinion

> “The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.”

Source: [Reilmann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618238/)

> “Prilenia and Ferrer announced that the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended refusal of marketing authorisation for pridopidine in HD.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-25"></a>

### Pridopidine: phase III PRECISE-HD in people not receiving antidopaminergic medications

> “PRECISE-HD is a randomised, placebo-controlled, double-blind, phase III interventional study evaluating pridopidine 45 mg twice daily in adults with HD who have not used anti-dopaminergic medications for at least six months before screening.”
> “The primary outcome measure is change from baseline to week 52 in cUHDRS score.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-26"></a>

### Approved AAV gene therapy: Kebilidi indication under accelerated approval

> “KEBILIDI is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

> “This indication is approved under accelerated approval based on the change from baseline in”
> “gross motor milestone achievement at 48 weeks post-treatment”

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

<a id="topic-2.1.2.14-27"></a>

### Kebilidi: accelerated approval on a single-arm study compared with an external natural history cohort

> “Specifically, a single-arm pivotal clinical study (n=13) and an external control natural history cohort comprised the adequate and well controlled investigation.”
> “The review team recommends accelerated approval of KEBILIDI based on an intermediate clinical endpoint of motor milestone achievement at Week 48 compared to an untreated natural history cohort.”
> “The Applicant submitted cross-sectional data from an external cohort of 44 untreated patients with severe AADCD as a comparator group.”
> “In comparison, none of the 44 untreated patients had documented motor milestone achievement at last assessment.”
> “These pharmacodynamic effects on AADC disease-specific biomarkers reflect a direct treatment effect of the product on the molecular pathway of the disease and provide strong confirmatory evidence of effectiveness.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

<a id="topic-2.1.2.14-28"></a>

### Kebilidi: confirmatory evidence required for continued approval

> “Continued approval for this indication is contingent upon verification of the long-term clinical benefit in a confirmatory study.”
> “As such, the review team recommends accelerated approval based on gross motor milestone achievement at Week 48 with a post-marketing requirement to provide longer-term efficacy data to verify and describe the clinical benefit as well as demonstrate durability of the efficacy of KEBILIDI in patients with AADCD.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

<a id="topic-2.1.2.14-29"></a>

### Direct head-to-head comparison of ifezuntirgene inilparvovec with an approved or investigational therapy

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
